Investigators assessed long-term PFS and safety results for acalabrutinib, bendamustine, and rituximab in the phase 3 ECHO trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback